Magenta pauses MGTA-117 Phase 1/2 trial after participant death possibly related to drug

Dianthus Therapeutics, Inc. /DE/

Latest participant dosed at Cohort 3 level (0.08 mg/kg) experienced Grade 5 SAE: respiratory failure and cardiac arrest leading to death.
Death deemed possibly related to MGTA-117; reported to FDA as Suspected Unexpected Serious Adverse Reaction (SUSAR).
Magenta voluntarily paused dosing after consultation with the trial's safety Cohort Review Committee.
Trial is in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.